Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01326702 · OUTCOME

Response Rate

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors · Source last updated 2019-12-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
2 years

What was measured

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI and/or CT: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for a Partial Response nor sufficient increase to qualify for Progression of Disease (POD); POD, 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Complete Response (CR), Disappearance of all target lesions.

Groups in this outcome

Dose Level 1-Bendamustine 70 mg/m2, ABT-888 50 mg

Bendamustine 70 mg/m2, ABT-888 50 mg

Dose Level 2: Bendamustine 90 mg/m2, ABT-888 50 mg

Bendamustine 90 mg/m2, ABT-888 50 mg

Dose Level 3: Bendamustine 90 mg/m2, ABT-888 100 mg BID

Bendamustine 90 mg/m2, ABT-888 100 mg BID

Dose Level 4: Bendamustine 90 mg/m2, ABT-888 150 mg BID

Bendamustine 90 mg/m2, ABT-888 150 mg BID

Dose Level 5: Bendamustine 90 mg/m2, ABT-888 200 mg BID

Bendamustine 90 mg/m2, ABT-888 200 mg BID

Dose Level 6: Bendamustine 90 mg/m2, ABT-888 300 mg BID

Bendamustine 90 mg/m2, ABT-888 300 mg BID

Dose Level 7: Bendamustine 90 mg/m2, ABT-888 400 mg BID

Bendamustine 90 mg/m2, ABT-888 400 mg BID

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Dose Level 1-Bendamustine 70 mg/m2, ABT-888 50 mg3
Dose Level 2: Bendamustine 90 mg/m2, ABT-888 50 mg3
Dose Level 3: Bendamustine 90 mg/m2, ABT-888 100 mg BID5
Dose Level 4: Bendamustine 90 mg/m2, ABT-888 150 mg BID2
Dose Level 5: Bendamustine 90 mg/m2, ABT-888 200 mg BID3
Dose Level 6: Bendamustine 90 mg/m2, ABT-888 300 mg BID14
Dose Level 7: Bendamustine 90 mg/m2, ABT-888 400 mg BID2

Reported measurements

Complete Response
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Dose Level 1-Bendamustine 70 mg/m2, ABT-888 50 mg0Not reportedNot reportedNot reportedNot reported
Dose Level 2: Bendamustine 90 mg/m2, ABT-888 50 mg0Not reportedNot reportedNot reportedNot reported
Dose Level 3: Bendamustine 90 mg/m2, ABT-888 100 mg BID1Not reportedNot reportedNot reportedNot reported
Dose Level 4: Bendamustine 90 mg/m2, ABT-888 150 mg BID0Not reportedNot reportedNot reportedNot reported
Dose Level 5: Bendamustine 90 mg/m2, ABT-888 200 mg BID0Not reportedNot reportedNot reportedNot reported
Dose Level 6: Bendamustine 90 mg/m2, ABT-888 300 mg BID4Not reportedNot reportedNot reportedNot reported
Dose Level 7: Bendamustine 90 mg/m2, ABT-888 400 mg BID0Not reportedNot reportedNot reportedNot reported
Partial Response
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Dose Level 1-Bendamustine 70 mg/m2, ABT-888 50 mg1Not reportedNot reportedNot reportedNot reported
Dose Level 2: Bendamustine 90 mg/m2, ABT-888 50 mg1Not reportedNot reportedNot reportedNot reported
Dose Level 3: Bendamustine 90 mg/m2, ABT-888 100 mg BID0Not reportedNot reportedNot reportedNot reported
Dose Level 4: Bendamustine 90 mg/m2, ABT-888 150 mg BID0Not reportedNot reportedNot reportedNot reported
Dose Level 5: Bendamustine 90 mg/m2, ABT-888 200 mg BID1Not reportedNot reportedNot reportedNot reported
Dose Level 6: Bendamustine 90 mg/m2, ABT-888 300 mg BID4Not reportedNot reportedNot reportedNot reported
Dose Level 7: Bendamustine 90 mg/m2, ABT-888 400 mg BID0Not reportedNot reportedNot reportedNot reported
Stable Disease
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Dose Level 1-Bendamustine 70 mg/m2, ABT-888 50 mg1Not reportedNot reportedNot reportedNot reported
Dose Level 2: Bendamustine 90 mg/m2, ABT-888 50 mg2Not reportedNot reportedNot reportedNot reported
Dose Level 3: Bendamustine 90 mg/m2, ABT-888 100 mg BID2Not reportedNot reportedNot reportedNot reported
Dose Level 4: Bendamustine 90 mg/m2, ABT-888 150 mg BID2Not reportedNot reportedNot reportedNot reported
Dose Level 5: Bendamustine 90 mg/m2, ABT-888 200 mg BID0Not reportedNot reportedNot reportedNot reported
Dose Level 6: Bendamustine 90 mg/m2, ABT-888 300 mg BID5Not reportedNot reportedNot reportedNot reported
Dose Level 7: Bendamustine 90 mg/m2, ABT-888 400 mg BID0Not reportedNot reportedNot reportedNot reported
Progression of Disease
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Dose Level 1-Bendamustine 70 mg/m2, ABT-888 50 mg1Not reportedNot reportedNot reportedNot reported
Dose Level 2: Bendamustine 90 mg/m2, ABT-888 50 mg0Not reportedNot reportedNot reportedNot reported
Dose Level 3: Bendamustine 90 mg/m2, ABT-888 100 mg BID2Not reportedNot reportedNot reportedNot reported
Dose Level 4: Bendamustine 90 mg/m2, ABT-888 150 mg BID0Not reportedNot reportedNot reportedNot reported
Dose Level 5: Bendamustine 90 mg/m2, ABT-888 200 mg BID2Not reportedNot reportedNot reportedNot reported
Dose Level 6: Bendamustine 90 mg/m2, ABT-888 300 mg BID1Not reportedNot reportedNot reportedNot reported
Dose Level 7: Bendamustine 90 mg/m2, ABT-888 400 mg BID2Not reportedNot reportedNot reportedNot reported
Complete source fields
calculate Pct
false
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        1
      4. group Id
        OG003
        value
        0
      5. group Id
        OG004
        value
        0
      6. group Id
        OG005
        value
        4
      7. group Id
        OG006
        value
        0
    title
    Complete Response
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        1
      3. group Id
        OG002
        value
        0
      4. group Id
        OG003
        value
        0
      5. group Id
        OG004
        value
        1
      6. group Id
        OG005
        value
        4
      7. group Id
        OG006
        value
        0
    title
    Partial Response
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        2
      3. group Id
        OG002
        value
        2
      4. group Id
        OG003
        value
        2
      5. group Id
        OG004
        value
        0
      6. group Id
        OG005
        value
        5
      7. group Id
        OG006
        value
        0
    title
    Stable Disease
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        2
      4. group Id
        OG003
        value
        0
      5. group Id
        OG004
        value
        2
      6. group Id
        OG005
        value
        1
      7. group Id
        OG006
        value
        2
    title
    Progression of Disease
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      3
    3. group Id
      OG002
      value
      5
    4. group Id
      OG003
      value
      2
    5. group Id
      OG004
      value
      3
    6. group Id
      OG005
      value
      14
    7. group Id
      OG006
      value
      2
    units
    Participants
description
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI and/or CT: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for a Partial Response nor sufficient increase to qualify for Progression of Disease (POD); POD, 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Complete Response (CR), Disappearance of all target lesions.
groups
  1. description
    Bendamustine 70 mg/m2, ABT-888 50 mg
    id
    OG000
    title
    Dose Level 1-Bendamustine 70 mg/m2, ABT-888 50 mg
  2. description
    Bendamustine 90 mg/m2, ABT-888 50 mg
    id
    OG001
    title
    Dose Level 2: Bendamustine 90 mg/m2, ABT-888 50 mg
  3. description
    Bendamustine 90 mg/m2, ABT-888 100 mg BID
    id
    OG002
    title
    Dose Level 3: Bendamustine 90 mg/m2, ABT-888 100 mg BID
  4. description
    Bendamustine 90 mg/m2, ABT-888 150 mg BID
    id
    OG003
    title
    Dose Level 4: Bendamustine 90 mg/m2, ABT-888 150 mg BID
  5. description
    Bendamustine 90 mg/m2, ABT-888 200 mg BID
    id
    OG004
    title
    Dose Level 5: Bendamustine 90 mg/m2, ABT-888 200 mg BID
  6. description
    Bendamustine 90 mg/m2, ABT-888 300 mg BID
    id
    OG005
    title
    Dose Level 6: Bendamustine 90 mg/m2, ABT-888 300 mg BID
  7. description
    Bendamustine 90 mg/m2, ABT-888 400 mg BID
    id
    OG006
    title
    Dose Level 7: Bendamustine 90 mg/m2, ABT-888 400 mg BID
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
2 years
title
Response Rate
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice